key: cord-0759668-v3w2ssld
authors: Singh, Yogendra; Fuloria, Neeraj Kumar; Fuloria, Shivkanya; Subramaniyan, Vetriselvan; Almalki, Waleed Hassan; Al‐abbasi, Fahad A.; Kazmi, Imran; Rajput, Sobhit Singh; Joshi, Nirmal; Gupta, Gaurav
title: A European pharmacotherapeutic agent roflumilast exploring integrated preclinical and clinical evidence for SARS CoV‐2 mediated inflammation to organ damage
date: 2022-03-30
journal: Br J Clin Pharmacol
DOI: 10.1111/bcp.15328
sha: 5236365324e2656b792f0bb6e9cc41362a5c00da
doc_id: 759668
cord_uid: v3w2ssld

COVID‐19 has spread globally, affecting almost 160 million individuals. Elderly and pre‐existing patients (such as diabetes, heart disease and asthma) seem more susceptible to severe illness with COVID‐19. Roflumilast was licensed for usage in the European Union in July 2010 as a phosphodiesterase‐4 (PDE4) inhibitor. Under preclinical studies, roflumilast has been shown to decrease bleomycin‐induced lung fibrosis, lung hydroxyproline and right heart thickening. The current study reviewed existing data that the PDE‐4 inhibitor, a roflumilast, protects renal tissues and other major organ systems after COVID‐19 infection by decreasing immune cell infiltration. These immune‐balancing effects of roflumilast were related to a decrease in oxidative and inflammatory burden, caspase‐3 suppression and increased protein kinase A (PKA)/cyclic A.M.P. (cAMP) levels in renal and other organ tissue.

Gaurav Gupta, Department of Pharmacology, School of Pharmacy, Suresh Gyan Vihar University, Mahal Road, Jagatpura, Jaipur, India. Email: gauravpharma25@gmail.com COVID-19 has spread globally, affecting almost 160 million individuals. Elderly and pre-existing patients (such as diabetes, heart disease and asthma) seem more susceptible to severe illness with COVID-19. Roflumilast was licensed for usage in the European Union in July 2010 as a phosphodiesterase-4 (PDE4) inhibitor. Under preclinical studies, roflumilast has been shown to decrease bleomycin-induced lung fibrosis, lung hydroxyproline and right heart thickening. The current study reviewed existing data that the PDE-4 inhibitor, a roflumilast, protects renal tissues and other major organ systems after COVID-19 infection by decreasing immune cell infiltration. increased risk of death. 8, 9 Roflumilast was licensed for usage in the European Union in July 2010 as a PDE4 inhibitor. Roflumilast has been approved as a 'constraint' treatment to bronchodilators by the E.M.A. summary and, under the GOLD guidelines, an effect also exists in patients not controlled on the combination of Fixed-Dose LABAs like formoterol and I.C.S. such as beclomethasone dipropionate. Moreover, roflumilast coadministration with budesonide in Asians and Caucasians did not affect the steady disposition of either drug and had no consequences for its safety or tolerability, denoting that it may be consumed without or with a meal. 10 However, roflumilast cessation might be because of the relatively costly medicine and, after complex prescription procedures or unpleasant effects, poor understanding of roflumilast indications between the clinicians. 11 A recent study found that roflumilast protects against the functional consequences of cerebral ischemia, which might be linked to its anti-inflammatory properties. 12 Another research also shows in particular that roflumilast inhibitor of PDE-4 prevents L.P.S. from releasing nitric oxide (NO), IL-1β, TNF-α from the production of the macrophage through suppression of activation of stress-activated protein kinases (SAPK)/c-Jun N-terminal kinases (J.N.K.), p38 mitogen-activated protein kinase (MAPK), nuclear factor-kappa B (NF-κB) mechanisms. 13 Roflumilast has been proven in animal preventative and curative studies to reduce bleomycin-induced lung fibrosis, lung hydroxyproline and right heart thickening; it has also been shown to prevent intracoronary pulmonary artery muscularization. The inhibitor PDE4 was utilized in the bronchoalveolar lavage fluid to diminish bleomycin-induced transcripts for TNF-α, transforming growth factor-beta (TGF-β), connective tissue growth factor synthesis, endothelin-1, aI(I)collagen and mucin Muc5ac in the lung, as well as to decrease the levels of IL-13, TNF-α and TGF-β. Moreover, lung fibrosis, al(I)collagen, right heart thickness generated by bleomycin have been reduced with roflumilast, but not dexamethasone group. 14 Additionally, another study found that roflumilast and roflumilast N-oxide suppressed the release of macrophages like cell attracting molecules and TNF-α release in the lungs. 15 Inflammation and immunological response are strongly related to increased PDE-4 synthesis. There are five major PDE-4 isoforms.

They are PDED-4A, PDED-4B, PDED-4C, PDED-4D and PDED-4E. PDE-4B is highly upregulated on neutrophils and monocytes, resulting in the discharge of many inflammation-inducing agents. 16 In contrast to earlier experimental findings, where L.P.S. injection was shown to stimulate TNF production from circulating leukocytes in PDE-4B knockout mice, it appears that this detrimental transcript effect in inflammatory conditions has been completely inhibited. 17 Additionally, suppression of PDE-4B repressed apoptotic cell death and inflammation molecule biosynthesis in the renal tubular epithelial cell when treated with cisplatin. Previously, when ovalbumin was given to rats' bronchiolar lavage fluid, PDE-4B/D expression was more significant than controls. The higher expression of these isoforms was noted in only the lavage fluid of rats with ovalbumin exposure.

However, the overexpression of PDE-4B only helped rescue allergic symptoms in this study. 18 The high-dose Roflumilast significantly Additionally, research indicates that roflumilast may be helpful in atherothrombotic disorders and inflammatory vasculitis that is not primarily associated with lung damage. 20 Notably, Roflumilast was found to improve glucose uptake and insulin sensitivity. This was linked with stimulation of the PKA/cAMP/CREB axis, which leads to PCG-1-dependent activation of mitochondrial energy production. Figure 1 Depicts the Possible Role of Roflumilast in SARS CoV-2 Mediated Inflammation to Organ Damage.

The current study reviewed existing data that the PDE-4 inhibitor protects renal tissues and other major organ systems after COVID-19 infection by decreasing immune cell infiltration. These immunebalancing effects of roflumilast were related to a decrease in oxidative and inflammatory burden, caspase-3 suppression and increased PKA/cAMP levels in renal and other organ tissue. The findings provide new information on the late-phase processes linked to COVID-19-related inflammation and the mechanisms behind roflumilast's organ-protective actions.

There was no specific funding for this study.

Acute kidney injury precipitating myocardial injury in a young male with COVID-19

Sepsis-induced acute kidney injury revisited: pathophysiology, prevention and future therapies

Role of circulating lymphocytes in patients with sepsis

Beta (3)-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: correlation with leukocyte recruitment to adherent platelets 1 hour after injury

Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo

The emerging threat of (micro) thrombosis in COVID-19 and its therapeutic implications

The trinity of COVID-19: immunity, inflammation and intervention

Neutrophils in COVID-19

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide

Roflumilast usage from 2010 to 2016: a Danish Nationwide Drug Utilization Study

Roflumilast protects against spatial memory impairments and exerts anti-inflammatory effects after transient global cerebral ischemia

Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation

Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury

Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide

Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils

Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses

Anti-inflammatory effect of ciclamilast in an allergic model involving the expression of PDE4B

Essential role of CCR2 in neutrophil tissue infiltration and multiple organ dysfunction in sepsis

Roflumilast inhibits leukocyte-platelet interactions and prevents the prothrombotic functions of polymorphonuclear leukocytes and monocytes

A European pharmacotherapeutic agent roflumilast exploring integrated preclinical and clinical evidence for SARS CoV-2 mediated inflammation to organ damage

The authors declare no competing interest. 

No datasets were generated or analysed during the current study.

https://orcid.org/0000-0001-6132-5106